Abstract
Lipid formulations of amphotericin B are increasingly used in lieu of deoxycholate amphotericin B for primary treatment of zygomycosis, but little is known about the efficacy of the former antifungal in treating this fungal disease. We therefore undertook an analysis of a case series of all patients with zygomycosis who received L-AMB for primary antifungal therapy in five major mid-Atlantic medical centers. Among the categories of variables studied were demographics, methods of diagnosis, microbiology, sites of infection, global responses, and survival. The median patient age was 44 years and 71% were male. Immunosuppressive hematological disorders (54%) were the most common underlying condition. Pulmonary disease constituted 50% of infections, sinus infection 29%, and cutaneous disease 18%. Members of the genus Rhizopus were the most common recovered agents. Success as defined by complete or partial positive response was noted in 32% of the cases. Concomitant surgery was performed in 46% of the cases, with similar response rates (31%). Overall survival was 39%. L-AMB was effective as primary therapy in only some patients in this cohort of highly immunocom-promised individuals with invasive zygomycosis underscoring the importance of host response and the need for further advances for treatment of this lethal infection.
Acknowledgments
This work was supported in part by the intramural program of the National Cancer Institute and by a grant from Astellas Healthcare Inc.
Declaration of interest: Dr Shoham has received research support from Astellas Pharma US, Inc., Pfizer Inc., Merck and Co., Inc., and Enzon Inc. and honoraria for speaking on behalf of or consulting for: Astellas Pharma US, Inc., Pfizer Inc., Merck and Co., Inc., Enzon Inc., and ScheringPlough Corporation.
Dr Magill has received research support from, and consulted for, Pfizer Inc. and received an honorarium from Astellas Pharma US, Inc.
This paper was first published online on Early Online on 12 October 2009.